Efinaconazole in the treatment of onychomycosis

References

• GhannoumMAHajjehRAScherRA large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patternsJ Am Acad Dermatol200043464164811004620
   PubMed Web of Science ®Google Scholar
• ScherRKRichPPariserDElewskiBThe epidemiology, etiology, and pathophysiology of onychomycosisSemin Cutan Med Surg2013322 suppl 1S2S424156160
   PubMed Web of Science ®Google Scholar
• ScherRKBaranROnychomycosis in clinical practice: factors contributing to recurrenceBr J Dermatol2003149suppl 655914510969
   PubMed Web of Science ®Google Scholar
• PiracciniBMSistiATostiALong-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agentsJ Am Acad Dermatol201062341141420159308
   PubMed Web of Science ®Google Scholar
• WelshOVera-CabreraLWelshEOnychomycosisClin Dermatol201028215115920347657
   PubMed Web of Science ®Google Scholar
• GuptaAKSauderDNShearNHAntifungal agents: an overview. Part IIJ Am Acad Dermatol1994306911933 [quiz 34–36]7619094
   PubMed Web of Science ®Google Scholar
• GuptaAKPaquetMSimpsonFTavakkolATerbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimensJ Eur Acad Dermatol Venereol201327326727222632057
   PubMed Web of Science ®Google Scholar
• DrakeLAShearNHArletteJPOral terbinafine in the treatment of toenail onychomycosis: North American multicenter trialJ Am Acad Dermatol1997375 pt 17407459366820
   PubMed Web of Science ®Google Scholar
• EvansEGSigurgeirssonBDouble blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study GroupBMJ199931871901031103510205099
   PubMed Web of Science ®Google Scholar
• Sporanox (itraconazole) [package insert], PricaraDivision of Ortho-McNeil-Janssen Pharmaceuticals, IncRaritan, NJ2011
   Google Scholar
• ScherRKBrenemanDRichPOnce-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenailJ Am Acad Dermatol1998386 pt 2S77S869631989
   PubMed Web of Science ®Google Scholar
• BaranRSigurgeirssonBde BerkerDA multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvementBr J Dermatol2007157114915717553051
   PubMed Web of Science ®Google Scholar
• PolakAPreclinical data and mode of action of amorolfineDermatology1992184Suppl 1371550968
   PubMed Web of Science ®Google Scholar
• BelenkyPCamachoDCollinsJJFungicidal drugs induce a common oxidative-damage cellular death pathwayCell Rep20133235035823416050
   PubMed Web of Science ®Google Scholar
• LeeRELiuTTBarkerKSLeeRERogersPDGenome-wide expression profiling of the response to ciclopirox olamine in Candida albicansJ Antimicrob Chemother200555565566215814599
   PubMed Web of Science ®Google Scholar
• Penlac nail lacquer (ciclopirox) topical solution 8% [package insert]Dermik LaboratoriesBerwyn, PA2003
   Google Scholar
• Jo SiuWJTatsumiYSendaHComparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosisAntimicrob Agents Chemother20135741610161623318803
   PubMed Web of Science ®Google Scholar
• OguraHKobayashiHNagaiKSynthesis and antifungal activities of (2R,3R)-2-aryl-1-azolyl-3-(substituted amino)-2-butanol derivatives as topical antifungal agentsChem Pharm Bull199947101417142510553638
   PubMed Web of Science ®Google Scholar
• RodriguezRJLowCBottemaCDParksLWMultiple functions for sterols in Saccharomyces cerevisiaeBiochim Biophys Acta198583733363433904834
   PubMed Web of Science ®Google Scholar
• ParksLWSmithSJCrowleyJHBiochemical and physiological effects of sterol alterations in yeast – a reviewLipids19953032272307791530
   PubMed Web of Science ®Google Scholar
• TatsumiYNagashimaMShibanushiTMechanism of action of efinaconazole, a novel triazole antifungal agentAntimicrob Agents Chemother20135752405240923459486
   PubMed Web of Science ®Google Scholar
• Council\USANStatement on a Nonproprietary Name Adopted by the USAN Council: Efinaconazole Available from: http://www.ama-assn.org/resources/doc/usan/efinaconazole.pdfAccessed April 28, 2015
   Google Scholar
• LLC VPNAJublia (Efinaconazole) Package InsertBridgewaterNJ, USA2014 Available from: http://www.accessdata.fda.gov/drug-satfda_docs/label/2014/203567s000lbl.pdf
   Google Scholar
• KircikLHEnhancing transungual delivery and spreading of efinaconazole under the nail plate through a unique formulation approachJ Drugs Dermatol201413121457146125607788
   PubMed Web of Science ®Google Scholar
• SakamotoMSugimotoNKawabataHTransungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nailsJ Drugs Dermatol201413111388139225607707
   PubMed Web of Science ®Google Scholar
• ElewskiBEPollakRAPillaiROlinJTAccess of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual spaceJ Drugs Dermatol201413111394139825607708
   PubMed Web of Science ®Google Scholar
• ArikaTYokooMHaseTMaedaTAmemiyaKYamaguchiHEffects of butenafine hydrochloride, a new benzylamine derivative, on experimental dermatophytosis in guinea pigsAntimicrob Agents Chemother19903411225022532073116
   PubMed Web of Science ®Google Scholar
• TatsumiYYokooMArikaTYamaguchiHIn vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous can-didiasis in guinea pigsAntimicrob Agents Chemother20014551493149911302816
   PubMed Web of Science ®Google Scholar
• TatsumiYYokooMArikaTYamaguchiHKP-103, a novel triazole derivative, is effective in preventing relapse and successfully treating experimental interdigital tinea pedis and tinea corporis in guinea pigsMicrobiol Immunol200246742543212222928
   PubMed Web of Science ®Google Scholar
• TatsumiYYokooMArikaTYamaguchiHIn vivo fungicidal effect of KP-103 in a guinea pig model of interdigital tinea pedis determined by using a new method for removing the antimycotic carryover effectMicrobiol Immunol200246743343912222929
   PubMed Web of Science ®Google Scholar
• TatsumiYYokooMSendaHKakehiKTherapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafineAntimicrob Agents Chemother200246123797380112435679
   PubMed Web of Science ®Google Scholar
• SugiuraKSugimotoNHosakaSThe low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatmentAntimicrob Agents Chemother20145873837384224752277
   PubMed Web of Science ®Google Scholar
• IwataAWatanabeYKumagaiNIn vitro and in vivo assessment of dermatophyte acquired resistance to efinaconazole, a novel triazole antifungalAntimicrob Agents Chemother20145884920492224867968
   PubMed Web of Science ®Google Scholar
• LipnerSScherRKOnychomycosis: current and future therapiesCutis2014932606324605341
   PubMed Web of Science ®Google Scholar
• DiaoYZhaoRDengXLengWPengJJinQTranscriptional profiles of Trichophyton rubrum in response to itraconazoleMed Mycol200947323724718663659
   PubMed Web of Science ®Google Scholar
• JarrattMSiuWJYamakawaEKoderaNPillaiRSmithKSafety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosisJ Drugs Dermatol20131291010101624002148
   PubMed Web of Science ®Google Scholar
• HardinTCGraybillJRFetchickRWoestenborghsRRinaldiMGKuhnJGPharmacokinetics of itraconazole following oral administration to normal volunteersAntimicrob Agents Chemother1988329131013132848442
   PubMed Web of Science ®Google Scholar
• KovarikJMMuellerEAZehenderHDenouelJCaplainHMilleriouxLMultiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolitesAntimicrob Agents Chemother19953912273827418593011
   PubMed Web of Science ®Google Scholar
• TschenEHBuckoADOizumiNKawabataHOlinJTPillaiREfinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind studyJ Drugs Dermatol201312218619223377392
   PubMed Web of Science ®Google Scholar
• ElewskiBERichPPollakREfinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studiesJ Am Acad Dermatol201368460060823177180
   PubMed Web of Science ®Google Scholar
• Del RossoJQReeceBSmithKMillerTEfinaconazole 10% solution: a new topical treatment for onychomycosis: contact sensitization and skin irritation potentialJ Clin Aesthet Dermatol2013632024
   Google Scholar
• JoWGlynnMNejishimaHNonclinical safety assessment of efinaconazole solution (10%) for onychomycosis treatmentRegul Toxicol Pharmacol201470124225325038564
   PubMed Web of Science ®Google Scholar
• GlynnMJoWMinowaKEfinaconazole: developmental and reproductive toxicity potential of a novel antifungal azoleReprod Toxicol201452182525527861
   PubMed Web of Science ®Google Scholar
• RobbinsJMTreatment of onychomycosis in the diabetic patient populationJ Diabetes Complications20031729810412614976
   PubMed Web of Science ®Google Scholar
• VlahovicTCJosephWSEfinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetesJ Drugs Dermatol201413101186119025607552
   PubMed Web of Science ®Google Scholar
• JenningsMBPollakRHarklessLBKianifardFTavakkolATreatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trialJ Am Podiatr Med Assoc200696646547317114599
   PubMed Web of Science ®Google Scholar
• LipnerSRScherRKOnychomycosisRazzaghi-AbyanehMMedical Mycology: Past, Present and FutureUSACRC; In press2015
   Google Scholar
• MarkinsonBCCaldwellBDEfinaconazole Topical Solution, 10%: Efficacy in Patients with Onychomycosis and Coexisting Tinea PedisJ Am Podiatr Med Assoc Epub2015413
   PubMed Web of Science ®Google Scholar
• SzepietowskiJCReichAGarlowskaEKuligMBaranEOnychomycosis Epidemiology Study GroupFactors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patientsArch Dermatol2006142101279128417043182
   PubMed Web of Science ®Google Scholar
• RichPEfinaconazole topical solution, 10%: the benefits of treating onychomycosis earlyJ Drugs Dermatol2015141586225607909
   PubMed Web of Science ®Google Scholar
• ZeichnerJAStein GoldLKorotzerAPenetration of ((14)C)-efinaconazole topical solution, 10%, does not appear to be influenced by nail polishJ Clin Aesthet Dermatol201479343625276275
   PubMedGoogle Scholar
• ZeichnerJAStein GoldLKorotzerAErratum: penetration of (14C)-efinaconazole 10% solution does not appear to be influenced by nail polishJ Clin Aesthet Dermatol2014711825599721
   PubMedGoogle Scholar
• ScheinJRGauseDStierDMLubeckDPBatesMMFiskROnychomycosis. Baseline results of an observational studyJ Am Podiatr Med Assoc199787115125199397656
   PubMed Web of Science ®Google Scholar
• ChaconAFrancaKFernandezANouriKPsychosocial impact of onychomycosis: a reviewInt J Dermatol201352111300130724164152
   PubMedGoogle Scholar
• TostiAElewskiBETreatment of onychomycosis with efinaconazole 10% topical solution and quality of lifeJ Clin Aesthet Dermatol2014711253025489379
   PubMedGoogle Scholar
• PatelTDhillonSEfinaconazole: first global approvalDrugs201373171977198324249649
   PubMed Web of Science ®Google Scholar
• LtdKPCR&D Pipeline2013 [January 25, 2015]. Available from: http://www.kaken.co.jp/english/rd_pipeline.html
   Google Scholar
• Inc VPIValeant Pharmaceuticals Announces Receipt of US FDA Complete Response Letter for Efinaconazole2013 [January 26, 2014]. Available from: http://ir.valeant.com/investor-relations/news-releases/news-release-details/2013/Valeant-Pharmaceuticals-Announces-Receipt-Of-US-FDA-Complete-Response-Letter-For-Efinaconazole
   Google Scholar